

**University of La Verne
Institutional Review Board (IRB)**

For The

Protection of Human Participants in Research

PAYMENT TO RESEARCH PARTICIPANTS

The institutional Review Board (IRB) must review all potential benefits to subjects to determine:

(1) that the risks to participants are in relation to anticipated benefits [21 CFR 56.111 (1) (2)];

and (2) that the consent form contains an adequate description of the benefits of participating in

the study [21 CFR 50.25(a) (3)]. Payment to research participants for participation in studies is

considered a benefit.

It is not uncommon for participants to be paid for their participation in the early phases of

investigational drug or device development. In such cases the IRB should review both the amount of payment and the proposed method of disbursement to assure that neither present

problems of coercion or undue influence (21 CFR 50.20). Such problems might occur, for example, if the entire payment were to be contingent upon completion of the study or if the

payment were unduly large.

All information concerning payment, including the amount and schedule of payment, must be set

forth in the informed consent form.

For specific information, please contact:

IF YOU HAVE ANY QUESTIONS

Please contact the University Research Coordinator of the Institutional Review Board at (909) 593-3511, ext. 4579.

FOR FURTHER INFORMATION, PLEASE CONTACT

Paula Waterman, Public Health Advisor

Health Assessment Policy Staff

Office of Health Affairs (HFY)-20

Room 1522, 5600 Fishers Lane

Rockville, MD 20857

(301) 443-1382

(Page 1 of 1)